Halozyme Therapeutics, Inc. insider trading

Every open-market purchase and sale by Halozyme Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $113M 153 trades by 9 insiders 3 months later: median −4.7% (−8.7% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Halozyme Therapeutics, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Halozyme Therapeutics, Inc.’s insiders pay?

From August 10, 2011 to March 10, 2026, 21 insiders reported 20 open-market purchases and 35 sales not made under a pre-set plan in Halozyme Therapeutics, Inc. Twelve months after each purchase was reported, the shares were +9.9% against the S&P 500 on average (median −31.8%), over 20 purchases with a full year of prices; 45% beat the index. After sales, the shares moved −10.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 11, 2011 into $49,316 by November 2, 2026, +11.1% a year. It held shares 37% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $41,254 (+9.8% a year), and held throughout $84,155 (+15.1%).

Copying Halozyme Therapeutics, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Halozyme Therapeutics, Inc.'s insiders from August 11, 2011, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 37% of the time.

Halozyme Therapeutics, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Kirk Randal J	10% owner	6	−48.4% (6)	0%	6	−10.2% (6)	August 28, 2018
Kelley Kenneth J	Director	3	+37.2% (3)	67%	5	−47.7% (5)	December 7, 2020
Engler Robert	Director	2	+32.5% (2)	50%	2	+93.4% (2)	August 18, 2014
Daly James M	Director	0	—	—	3	−8.0% (3)	August 15, 2023
Posard Matthew L.	Director	0	—	—	3	−17.5% (3)	August 14, 2024
Torley Helen	PRESIDENT AND CEO	1	+94.0% (1)	100%	2	−47.6% (2)	February 21, 2023
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	0	—	—	2	—	March 10, 2026
Falberg Kathryn E	Director	2	+70.7% (2)	100%	0	—	August 14, 2013
Frost Gregory Ian	CEO, President	2	−17.8% (2)	50%	0	—	August 14, 2012
Henderson Jeffrey William	Director	0	—	—	2	−44.3% (2)	March 1, 2023
Labrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	0	—	—	2	−44.8% (2)	February 21, 2023
Matsui Connie	Director	0	—	—	2	+24.9% (2)	November 5, 2021
Patton John Stuart	Director	0	—	—	2	+30.3% (2)	August 21, 2014
Bizzari Jean-Pierre	Director	0	—	—	1	+7.9% (1)	August 25, 2021
Chondros Dimitrios	SVP, Chief Medical Officer	0	—	—	1	+51.5% (1)	August 5, 2019
Gustafson Kurt A	Vice President and CFO	1	−36.3% (1)	0%	0	—	August 10, 2011
Labarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	0	—	—	1	−48.4% (1)	February 21, 2023
Ramsay David A	VP and Chief Financial Officer	1	+94.0% (1)	100%	0	—	September 16, 2014
Shaffer James P	VP & Chief Commercial Officer	1	+118.7% (1)	100%	0	—	November 14, 2012
Shepard H. Michael	VP, Chief Scientific Officer	0	—	—	1	−16.8% (1)	September 11, 2013
Stelzer Laurie	Chief Financial Officer	1	−63.0% (1)	0%	0	—	August 24, 2015

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Halozyme Therapeutics, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Halozyme Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged +42.2% against the index. After 2 selling crowds, −20.5%. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
February 28, 2023	4 selling	−38.0%	−24.4%	−47.2%
November 30, 2020	5 selling	+1.4%	−16.7%	−43.5%
November 28, 2014	2 buying	+71.0%	+101.9%	+100.0%
May 31, 2012	2 buying	−34.2%	−27.7%	−42.5%
August 31, 2011	3 buying	+36.6%	+52.4%	−33.4%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Halozyme Therapeutics, Inc. · Funds · Politicians